B.R.A.I.N. Biotechnology Research and Information Network AG (DE:BNN)
XETRA:BNN
Want to see DE:BNN full AI Analyst Report?
BNN Stock Chart & Stats
€2.50
€0.00(0.00%)
At close: 4:00 PM EST
€2.50
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.81 - €3.89
Previous CloseN/A
Volume750.00
Average Volume (3M)10.93K
Market Cap
€63.14M
Enterprise Value€64.57M
Total Cash (Recent Filing)€6.32M
Total Debt (Recent Filing)€24.03M
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding21,847,494
10 Day Avg. Volume22,707
30 Day Avg. Volume10,926
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)25.87
Price to Sales (P/S)0.96
P/FCF Ratio-4.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.26
Revenue Forecast (FY)€55.79M
Bulls Say, Bears Say
Bulls Say
Gross Margin ImprovementAn improvement in gross margin indicates the company has taken steps to reduce direct costs or improve pricing; if sustained this materially supports a path toward operating leverage, making future profitability easier to achieve even if top-line growth remains challenged.
Free Cash Flow Trending BetterA less negative free cash flow year-over-year reduces immediate external funding needs and signals incremental progress in cash conversion. If this trend persists it lowers refinancing frequency and dilution risk, improving long-term funding stability for R&D and operations.
Established Operational HeadcountMaintaining a workforce of nearly 300 employees preserves institutional knowledge and operational capacity for research and development. In biotech, sustained human capital and capabilities support long-duration projects and can enable execution of clinical or product milestones over time.
Bears Say
Persistent Net LossesOngoing net losses across reporting periods indicate structural unprofitability. This erodes retained earnings and limits reinvestment capacity; sustained losses make it difficult to fund growth internally and increase dependence on external capital, risking dilution and impairing long-term solvency.
Weak Operating Cash GenerationPersistent negative operating cash flow shows the core business cannot self-fund operations. This creates recurring financing needs, increases vulnerability to capital markets conditions, and reduces resilience to delays in R&D or product commercialization, threatening long-term viability.
Elevated Balance Sheet LeverageA sharply weakened capital base and higher leverage reduce financial flexibility and increase refinancing and covenant risk. With limited equity cushion, adverse results or higher rates can force dilutive financing or constrained investment, undermining sustained R&D and commercialization plans.
BNN FAQ
What was B.R.A.I.N. Biotechnology Research and Information Network AG’s price range in the past 12 months?
B.R.A.I.N. Biotechnology Research and Information Network AG lowest stock price was €1.80 and its highest was €3.89 in the past 12 months.
What is B.R.A.I.N. Biotechnology Research and Information Network AG’s market cap?
B.R.A.I.N. Biotechnology Research and Information Network AG’s market cap is €63.14M.
When is B.R.A.I.N. Biotechnology Research and Information Network AG’s upcoming earnings report date?
B.R.A.I.N. Biotechnology Research and Information Network AG’s upcoming earnings report date is Aug 27, 2026 which is in 73 days.
How were B.R.A.I.N. Biotechnology Research and Information Network AG’s earnings last quarter?
B.R.A.I.N. Biotechnology Research and Information Network AG released its earnings results on May 28, 2026. The company reported -€0.29 earnings per share for the quarter, missing the consensus estimate of -€0.09 by -€0.2.
Is B.R.A.I.N. Biotechnology Research and Information Network AG overvalued?
According to Wall Street analysts B.R.A.I.N. Biotechnology Research and Information Network AG’s price is currently Overvalued.
Does B.R.A.I.N. Biotechnology Research and Information Network AG pay dividends?
B.R.A.I.N. Biotechnology Research and Information Network AG does not currently pay dividends.
What is B.R.A.I.N. Biotechnology Research and Information Network AG’s EPS estimate?
B.R.A.I.N. Biotechnology Research and Information Network AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does B.R.A.I.N. Biotechnology Research and Information Network AG have?
B.R.A.I.N. Biotechnology Research and Information Network AG has 21,847,494 shares outstanding.
What happened to B.R.A.I.N. Biotechnology Research and Information Network AG’s price movement after its last earnings report?
B.R.A.I.N. Biotechnology Research and Information Network AG reported an EPS of -€0.29 in its last earnings report, missing expectations of -€0.09. Following the earnings report the stock price went up 2.062%.
Which hedge fund is a major shareholder of B.R.A.I.N. Biotechnology Research and Information Network AG?
Currently, no hedge funds are holding shares in DE:BNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
B.R.A.I.N. Biotechnology Research and Information Network Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.50%
12-Months-Change
Fundamentals
Return on Equity
-1361.43%
Trailing 12-Months
Asset Growth
-25.24%
Trailing 12-Months
Company Description
B.R.A.I.N. Biotechnology Research and Information Network AG
Headquartered in Zwingenberg, Germany, and founded in 1993, BRAIN Biotech AG (renamed from B.R.A.I.N. Biotechnology Research and Information Network AG in April 2021) specializes in the discovery, development, production, and commercialization of advanced biological solutions. These include enzymes, biocatalysts, microorganisms, and naturally derived active compounds, catering to the chemical industry across Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two distinct segments: BioScience and BioIndustrial. The BioScience division is dedicated to uncovering and developing bioactive natural ingredients, such as sugar alternatives, taste modifiers, and other nature-based active components for diverse applications in the food, animal nutrition, skincare, cosmetics, and broader chemical sectors. Concurrently, the BioIndustrial segment focuses on identifying and optimizing enzymes and biocatalysts critical for manufacturing food and beverages, medical wound care products, lubricants, as well as for starch processing and bioethanol production. This segment also engineers microorganisms to serve as functional biomass for optimizing industrial manufacturing processes, converting greenhouse gas CO2 into a valuable industrial raw material, and facilitating the extraction of precious and rare earth metals. Furthermore, BRAIN Biotech AG has established strategic alliances with AnalytiCon Discovery GmbH and Roquette to jointly develop natural sweeteners and enhanced sweet taste solutions.